Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...

Stock futures are surging this morning after U.S. lawmakers passed a key procedural hurdle as part of an agreement that could bring an end to the shutdown that has lasted nearly six weeks; President ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

Just as U.S. households were fretting about the effect on travel and the wider economy of the longest-ever government ...

The US drug giant beat Novo Nordisk in the $10 bln battle for biotech Metsera with the help of the Federal Trade Commission.

Donald Trump engages in ad hoc agreements with individual companies and governments to expand his power. Some observers have described these actions as a new “economic nationalism”—but that term fails ...